Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients
Open Access
- 31 March 2012
- journal article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 66 (3), 376-386
- https://doi.org/10.1016/j.jaad.2011.03.012
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Regional variation in breast cancer treatment throughout the United StatesThe American Journal of Surgery, 2008
- Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trialsBritish Journal of Dermatology, 2008
- Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsJournal of the American Academy of Dermatology, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2008
- The Risk of Mortality in Patients With PsoriasisArchives of Dermatology, 2007
- Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)British Journal of Dermatology, 2007
- Pathogenesis and clinical features of psoriasisThe Lancet, 2007
- Do utilization management controls for phototherapy increase the prescription of biologics?Journal of Dermatological Treatment, 2006